Neurocrine Biosciences, Inc.  today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with ...

Neurocrine (NBIX) Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA capsules in adults with Huntington ...

By Lisa Lerer The country’s largest manufacturer of abortion pills is wading into the first major legal battle over abortion of President Trump’s second term. The company, GenBioPro ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s flagship product, INGREZZA, is used to treat tardive dyskinesia and chorea in Huntington’s disease. The company also offers CRENESSITY, a first-in ...

Abortion pill maker enters legal battle over FDA rules by Alejandra O’Connell-Domenech - 02/26/25 2:47 PM ET by Alejandra O’Connell-Domenech - 02/26/25 2:47 PM ET ...

The payer coverage changes suggests gradually increasing stringency around Ingrezza utilization, which may help explain Q4 weakness and the company’s disappointing FY25 guidance, the analyst ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

As a daily pill-taker, I’ve learned that the phrase “Out of sight, out of mind” holds all too true when it comes to staying on top of my medications. A pill case that looks and feels nice ...

Different types of birth control pills are available, including low-dose, extended-cycle, and conventional pills. It’s important to talk with a doctor to understand the benefits and risks and ...